Dexrazoxane treatment did not seem to compromise overall survival among pediatric patients with leukemia or lymphoma.
Bevacizumab has limited effectiveness and is therefore not likely to be cost effective in newly diagnosed glioblastoma multiforme.
Nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF metastatic melanoma.
Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age.
Population-based fecal immunochemical testing (FIT) screening in adults aged 50 to 69 years can reduce colorectal cancer (CRC) mortality.
Adhering to a Mediterranean diet may significantly reduce a woman's risk of endometrial cancer.
When radiotherapy was added to androgen deprivation therapy, only minimal impact on health-related quality-of-life in prostate cancer
Adding bevacizumab to standard treatment of glioblastoma may have no impact on health-related quality of life.
Talimogene laherparepvec (T-VEC) is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma.
Addition of bevacizumab to carboplatin/paclitaxel well tolerated in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC).
Many patients with cancer are interested in comprehensive tumor genetic profiling (CGP), and most are willing to pay out-of-pocket costs for CGP.
Vismodegib is safe and effective in the management of advanced basal cell carcinoma (BCC).
Second-line dovitinib in FGFR2-mutated and FGFR2-non-mutated advanced or metastatic endometrial cancer had single-agent activity.
Association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers.
A majority of people with a family history of colorectal cancer (CRC) are not getting screened for the disease early enough.
Azacitadine may be an important treatment option for older patients with newly diagnosed acute myeloid leukemia (AML).
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients.
A positive family history is not a significant independent risk factor for breast cancer outcome.
Undergoing chemotherapy before surgery may help women battling advanced ovarian cancer.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Malignant Gastric Outlet Obstruction
- Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System
- Adding Bevacizumab Has No Impact on Quality of Life in Glioblastoma
- Identifying Genetic Variations Associated with Risk of Prostate Cancer
- Colonoscopies Underperformed for Younger, High-Risk Americans
- Vitamin D Levels and Risk for Pancreatic Cancer
- New Screening Method May Identify Twice As Many Women with Ovarian Cancer
- Head and Neck Cancers Treatment Regimens
- Nicotinamide Safe, Effective for Non-Melanoma Skin Cancer Prevention in High-Risk Patients
- Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?
- Dexrazoxane Not Associated with Late Mortality in Pediatric Patients
- First-Line Bevacizumab for Glioblastoma Not Likely To Be Cost-Effective
- Nivolumab Appears Safe, Effective in Wild-Type, Mutant BRAF Melanoma
- Enoxaparin Efficacious, Feasible for Prevention of VTE in Advanced Pancreatic Cancer
- Primary Androgen Deprivation Raises Diabetes Risk by 60 Percent
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|